Evaluation of FGFR2b in context of relevant biomarkers supports potential combination of anti-FGFR2b with anti-PD-(L)1 therapy in gastric cancer

被引：2
|
作者：
Sharma, Khushboo [1 ]
Schmidt, Maike [1 ]
Hestir, Kevin [1 ]
Mendoza, Nerissa [1 ]
Powers, Janine [2 ]
Hnatyszyn, James [1 ]
机构：
[1] Five Prime Therapeut, San Francisco, CA USA
[2] Nurix Inc, San Francisco, CA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2019年 / 18卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-19-A033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A033
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy
    Maekawa, Naoya
    Konnai, Satoru
    Asano, Yumie
    Sajiki, Yamato
    Deguchi, Tatsuya
    Okagawa, Tomohiro
    Watari, Kei
    Takeuchi, Hiroto
    Takagi, Satoshi
    Hosoya, Kenji
    Kim, Sangho
    Ohta, Hiroshi
    Kato, Yukinari
    Suzuki, Yasuhiko
    Murata, Shiro
    Ohashi, Kazuhiko
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [12] Predictive value of fibroblast growth factor receptor (FGFR) mutations and gene fusions on anti-PD-(L)1 treatment outcomes in patients (pts) with advanced urothelial cancer (UC).
    Santiago-Walker, Ademi E.
    Chen, Fei
    Loriot, Yohann
    Siefker-Radtke, Arlene O.
    Sun, Libo
    Sundaram, Ramesh
    De Porre, Peter
    Patel, Kiran
    Wan, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [13] PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
    Yearley, Jennifer H.
    Gibson, Christopher
    Yu, Ni
    Moon, Christina
    Murphy, Erin
    Juco, Jonathan
    Lunceford, Jared
    Cheng, Jonathan
    Chow, Laura Q. M.
    Seiwert, Tanguy Y.
    Handa, Masahisa
    Tomassini, Joanne E.
    McClanahan, Terrill
    CLINICAL CANCER RESEARCH, 2017, 23 (12) : 3158 - 3167
  • [14] PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer
    Yearley, J.
    Gibson, C.
    Yu, N.
    Moon, C.
    Murphy, E.
    McClanahan, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S718 - S718
  • [15] Tracking circulating PD-L1-positive cells to monitor the outcome of patients with gastric cancer receiving anti-HER2 plus anti-PD-1 therapy
    Xiaoyi Chong
    Yanyan Li
    Jialin Lu
    Xujiao Feng
    Yilin Li
    Xiaotian Zhang
    Human Cell, 2024, 37 : 258 - 270
  • [16] Tracking circulating PD-L1-positive cells to monitor the outcome of patients with gastric cancer receiving anti-HER2 plus anti-PD-1 therapy
    Chong, Xiaoyi
    Li, Yanyan
    Lu, Jialin
    Feng, Xujiao
    Li, Yilin
    Zhang, Xiaotian
    HUMAN CELL, 2024, 37 (01) : 258 - 270
  • [17] A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer
    Tsimafeyeu, Ilya
    Statsenko, Galina
    Vladimirova, Liubov
    Besova, Natalia
    Artamonova, Elena
    Raskin, Grigory
    Rykov, Ivan
    Mochalova, Anastasia
    Utyashev, Igor
    Gorbacheva, Svetlana
    Kazey, Vasily
    Gavrilova, Evgenia
    Dragun, Nadezhda
    Moiseyenko, Vladimir
    Tjulandin, Sergei
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (02) : 324 - 332
  • [18] A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer
    Ilya Tsimafeyeu
    Galina Statsenko
    Liubov Vladimirova
    Natalia Besova
    Elena Artamonova
    Grigory Raskin
    Ivan Rykov
    Anastasia Mochalova
    Igor Utyashev
    Svetlana Gorbacheva
    Vasily Kazey
    Evgenia Gavrilova
    Nadezhda Dragun
    Vladimir Moiseyenko
    Sergei Tjulandin
    Investigational New Drugs, 2023, 41 : 324 - 332
  • [19] Predictive value of fibroblast growth factor receptor (FGFR) alterations on anti-PD-(L)1 treatment outcomes in patients (Pts) with advanced urothelial cancer (UC): Pooled analysis of real-world data
    Kim, William Y.
    Rose, Tracy L.
    Roghmann, Florian
    Eckstein, Markus
    Jarczyk, Jonas
    Zengerling, Friedemann
    Sikic, Danijel
    Breyer, Johannes
    Bolenz, Christian
    Hartmann, Arndt
    Mayhew, Gregory
    Shibata, Yoichiro
    Uronis, Joshua M.
    Galluzzi, Aaron
    Sundaram, Ramesh
    Xia, Qi
    Wu, Kathy
    Santiago-Walker, Ademi E.
    Erben, Philipp
    Wirtz, Ralph
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [20] Nivolumab Combined with Chemotherapy in FGFR2 and PD-L1 Co-Expressing Metastatic Gastric Cancer: A Prospective Phase 2 NIVOFGFR2 Study
    Tsimafeyeu, Ilya
    Musayeva, Gunel
    Mahmudova, Samira
    Otkhozoria, Nana
    Abbasov, Bahadur
    Kahharov, Alisher
    Guliyev, Fuad
    JOURNAL OF GASTROINTESTINAL CANCER, 2025, 56 (01)
12345